Denali Therapeutics Inc. $DNLI Shares Sold by Deutsche Bank AG

Key Points

• Deutsche Bank AG reduced its stake in Denali Therapeutics by 43.8%, now owning approximately 156,252 shares valued at $2.12 million.
• Multiple hedge funds have increased their holdings in Denali Therapeutics, with Polar Asset Management Partners Inc. raising their stake by an exceptional 1,240.9% in the last quarter.
• Analysts have offered mixed ratings on Denali’s stock, with a consensus rating of "Buy" and a target price averaging $33.62.

Deutsche Bank AG cut its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 43.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 156,252 shares of the company's stock after selling 121,601 shares during the quarter. Deutsche Bank AG owned about 0.11% of Denali Therapeutics worth $2,125,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Denali Therapeutics by 6.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company's stock valued at $62,335,000 after buying an additional 188,820 shares during the period. Dimensional Fund Advisors LP raised its holdings in Denali Therapeutics by 19.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock valued at $37,805,000 after buying an additional 295,594 shares during the period. Northern Trust Corp raised its holdings in Denali Therapeutics by 10.7% in the 4th quarter. Northern Trust Corp now owns 1,201,518 shares of the company's stock valued at $24,487,000 after buying an additional 115,876 shares during the period. Stempoint Capital LP raised its holdings in Denali Therapeutics by 107.2% in the 4th quarter. Stempoint Capital LP now owns 584,328 shares of the company's stock valued at $11,909,000 after buying an additional 302,278 shares during the period. Finally, Polar Asset Management Partners Inc. raised its holdings in Denali Therapeutics by 1,240.9% in the 4th quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company's stock valued at $11,231,000 after buying an additional 509,992 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DNLI. TD Cowen upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. HC Wainwright cut their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Robert W. Baird cut their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Finally, Bank of America cut their price target on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $33.62.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $14.51 on Thursday. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The company has a market cap of $2.12 billion, a PE ratio of -5.18 and a beta of 1.36. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. The business has a 50-day simple moving average of $14.28 and a 200-day simple moving average of $15.18.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.02. During the same period last year, the company earned ($0.59) EPS. On average, equities research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider directly owned 242,346 shares of the company's stock, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Carole Ho sold 2,937 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider directly owned 217,391 shares of the company's stock, valued at $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 501,962 shares of company stock valued at $7,520,799 over the last three months. 12.50% of the stock is owned by corporate insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.